Mounjaro vs Trulicity: Switching Between Them Safely

How Mounjaro and Trulicity Work Differently

Mounjaro (tirzepatide) is the first FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, while Trulicity (dulaglutide) activates the GLP-1 receptor alone. This distinction matters. GIP receptor activation amplifies insulin secretion in a glucose-dependent manner and appears to influence fat metabolism through pathways that GLP-1 stimulation alone does not fully engage 1.

The practical difference shows up in clinical outcomes. Tirzepatide's dual mechanism produces larger reductions in both blood sugar and body weight across the SURPASS trial program. Dulaglutide, approved over a decade ago, has a longer real-world track record and a completed cardiovascular outcomes trial (REWIND) showing reduced heart attacks, strokes, and cardiovascular death in patients with type 2 diabetes 2. That proven CV benefit is something Mounjaro has not yet matched with a finished dedicated outcomes trial. The ongoing SURPASS-CVOT study is expected to report results, but until then, clinicians weigh tirzepatide's metabolic superiority against dulaglutide's established cardiovascular evidence.

Both drugs are administered as once-weekly subcutaneous injections using prefilled auto-injector pens. Neither requires reconstitution or mixing. Storage requirements are similar: refrigerated until first use, then room temperature for a limited window (Mounjaro for 21 days, Trulicity for 14 days at up to 30°C) 3.

Head-to-Head Efficacy: What the Trials Show

No published trial directly compares tirzepatide to dulaglutide. The strongest indirect comparison comes from cross-trial analysis of the SURPASS and AWARD programs, which used overlapping patient populations with type 2 diabetes inadequately controlled on metformin.

In SURPASS-2 (N=1,879), tirzepatide 5 mg, 10 mg, and 15 mg reduced A1C by 2.01%, 2.24%, and 2.30% respectively at 40 weeks, compared with 1.86% for semaglutide 1 mg 1. Weight loss in the tirzepatide 15 mg group reached 12.4 kg versus 6.2 kg with semaglutide. By contrast, dulaglutide 1.5 mg in the AWARD-1 trial (N=978) lowered A1C by 1.51% at 26 weeks and produced approximately 2.3 kg of weight loss 4.

These are not apples-to-apples numbers. Trial durations differ. Baseline A1C values differ. Comparator arms differ. Still, the magnitude gap is large enough that the American Diabetes Association's 2024 Standards of Care positions tirzepatide as a preferred option when both glycemic control and weight management are treatment priorities 5.

The REWIND trial stands apart in the dulaglutide dataset. Over a median 5.4 years of follow-up in 9,901 patients with type 2 diabetes (31% with established cardiovascular disease), dulaglutide 1.5 mg reduced the composite MACE endpoint by 12% (HR 0.88, 95% CI 0.79-0.99) 2. That trial enrolled a broader population than most GLP-1 CV outcome studies, including patients with cardiovascular risk factors but no prior events.

When Clinicians Recommend Switching

The decision to switch between Mounjaro and Trulicity typically follows one of four clinical scenarios. A patient on Trulicity who is not reaching A1C or weight targets may be moved to Mounjaro for its stronger metabolic effects. A patient on Mounjaro who experiences persistent GI side effects at all dose levels might try Trulicity, which has a milder side-effect profile at lower doses. Insurance formulary changes can force a switch in either direction. And a patient with established cardiovascular disease on Trulicity may choose to remain on it specifically for the proven MACE reduction, even if Mounjaro offers better glucose numbers.

The 2024 ADA Standards of Care note that switching within the GLP-1 receptor agonist class is reasonable when the current therapy fails to meet individualized glycemic or weight goals, or when tolerability becomes a barrier to adherence 5. No washout period is required. The shared mechanism of action means patients already have receptor-level exposure, which can ease the transition.

"Switching between GLP-1-based therapies is common in clinical practice and generally straightforward when the new agent is initiated at its lowest approved dose," according to the Endocrine Society's 2023 clinical practice guideline on pharmacologic treatment of obesity 6.

Step-by-Step: How to Switch from Trulicity to Mounjaro

Start Mounjaro 2.5 mg on the day that the next Trulicity injection would have been due. Do not overlap doses. The 2.5 mg starting dose is mandatory regardless of the prior Trulicity dose (even if the patient was on dulaglutide 4.5 mg), because tirzepatide's dual receptor activity introduces a new pharmacologic stimulus that requires titration 3.

The Mounjaro label specifies 2.5 mg weekly for the first 4 weeks, then escalation to 5 mg. Dose increases of 2.5 mg increments can occur every 4 weeks thereafter, up to 15 mg. Patients switching from a high-dose GLP-1 agonist often tolerate faster titration with fewer GI symptoms than treatment-naive patients, but the prescribing information does not endorse skipping the 2.5 mg induction.

GI side effects (nausea, diarrhea, decreased appetite) peak during the first 2 weeks of each dose escalation. The nausea incidence with tirzepatide 5 mg in SURPASS-2 was 17.4%, declining to under 5% by week 12 1. Patients who tolerated Trulicity without GI issues may experience a brief recurrence during the Mounjaro titration phase.

Blood glucose monitoring should increase during the transition. The stronger glucose-lowering effect of tirzepatide can cause hypoglycemia if concurrent sulfonylurea or insulin doses are not reduced. The Mounjaro label recommends considering a reduction of the concomitant insulin dose by 20% when initiating tirzepatide in patients already on insulin 3.

Step-by-Step: How to Switch from Mounjaro to Trulicity

Start Trulicity 0.75 mg on the day the next Mounjaro injection would have been due. The 0.75 mg dose is used for the first 4 weeks, with escalation to 1.5 mg and potentially up to 3.0 mg or 4.5 mg depending on glycemic response 7.

This direction of switch is less common but not rare. Patients may move to Trulicity because of cost or formulary access, or because Mounjaro's GI side effects proved intractable even at the lowest dose. Some patients with established atherosclerotic cardiovascular disease and their clinicians prefer dulaglutide's proven MACE reduction from REWIND over Mounjaro's pending cardiovascular outcome data.

Expect A1C and weight to drift upward during the transition. Dulaglutide at its maximum 4.5 mg dose does not match the glycemic or weight effects of tirzepatide at 10-15 mg. A1C may rise by 0.3-0.8 percentage points depending on dose differential, and some weight regain is typical within the first 8-12 weeks. This is not a treatment failure. It reflects the pharmacologic ceiling difference between the two drugs.

"When stepping down from a dual-agonist to a single GLP-1 agonist, providers should counsel patients that some reduction in glucose and weight efficacy is expected," stated an ADA consensus report on sequential therapy in type 2 diabetes 5.

Weight Loss Comparison: Mounjaro vs Trulicity

Weight loss is often the deciding factor for patients evaluating these two drugs. The data gap is pronounced.

Tirzepatide at the 15 mg dose in SURPASS-2 produced a mean weight reduction of 12.4 kg (27.3 lb) over 40 weeks 1. The SURMOUNT-1 trial (N=2,539), which studied tirzepatide in adults with obesity or overweight without diabetes, showed even larger effects: 22.5% mean body weight reduction with tirzepatide 15 mg at 72 weeks 8.

Dulaglutide, by comparison, was not developed primarily as a weight-loss agent. In clinical trials for type 2 diabetes, weight loss with dulaglutide 1.5 mg ranged from 1.5 kg to 3.0 kg at 26-52 weeks 4. The higher 4.5 mg dose, approved in 2020, improved weight outcomes modestly (about 4.0-4.6 kg in post-hoc analyses), but these numbers remain far below tirzepatide's range.

For a patient whose primary goal is significant weight reduction alongside diabetes management, the data favor Mounjaro. For a patient who needs glucose control with modest weight loss and places high value on long-term cardiovascular safety data, Trulicity remains a defensible choice.

Side Effects: What Changes When You Switch

Both drugs share the GI side-effect profile common to all GLP-1 receptor agonists: nausea, vomiting, diarrhea, constipation, and decreased appetite. Tirzepatide's GI event rates in SURPASS-2 were higher than dulaglutide's in the AWARD trials, though cross-trial comparisons carry obvious limitations 1 4.

Injection site reactions differ modestly. Trulicity's Atrios auto-injector has been on the market since 2014 and generally receives favorable patient usability scores. Mounjaro's pen design is newer and functionally similar, though some patients report more injection-site erythema during the first few weeks 3.

Pancreatitis risk is a class-wide concern. The FDA label for both drugs includes pancreatitis warnings. In SURPASS-2, acute pancreatitis occurred in <0.2% of tirzepatide-treated patients. REWIND reported pancreatitis in 0.6% of dulaglutide-treated patients versus 0.5% on placebo over 5.4 years 2. Neither drug has shown a statistically significant increase in pancreatitis in large-scale trials, but patients with a history of pancreatitis should use caution with either agent.

Thyroid C-cell tumor warnings apply to both. This is a GLP-1 class labeling requirement based on rodent studies. Neither drug has demonstrated increased medullary thyroid carcinoma risk in human clinical trials, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 3 7.

Cost and Insurance Considerations

List prices for both drugs exceed $1,000 per month without insurance. Mounjaro's wholesale acquisition cost (WAC) is approximately $1,023 per 4-week supply at any dose. Trulicity's WAC is approximately $971 per 4-week supply. These figures change frequently and vary by pharmacy.

Insurance coverage is the practical determinant. Many commercial plans and Medicare Part D formularies include one but not the other as a preferred brand. Prior authorization requirements are common for both. Some payers require documented failure on metformin and/or a sulfonylurea before covering either injectable GLP-1 agent. Others mandate step therapy through a lower-cost GLP-1 option (often dulaglutide or semaglutide) before approving tirzepatide 9.

Manufacturer savings programs can reduce out-of-pocket costs to $25 per fill for eligible commercially insured patients. Eli Lilly (maker of both Mounjaro and Trulicity) has run savings card programs for each drug, though eligibility criteria and program terms shift quarterly.

When a formulary switch is forced (for instance, a payer dropping Trulicity from its preferred tier), the prescribing clinician typically files a prior authorization or formulary exception request. If denied, the patient switches to the covered agent at its lowest dose following the same protocol described above.

Who Should Stay on Trulicity Instead of Switching

Not every patient benefits from moving to Mounjaro. Patients at A1C goal on Trulicity with good tolerability have little clinical reason to switch unless weight loss is a separate unmet need. Patients with established atherosclerotic cardiovascular disease may prefer dulaglutide's REWIND-validated 12% MACE reduction until tirzepatide's SURPASS-CVOT data are published 2.

Patients on dulaglutide 0.75 mg for mild glycemic elevation and minimal weight concerns represent another group where escalation to Mounjaro may introduce unnecessary side-effect risk. A dose increase to dulaglutide 1.5 mg or 3.0 mg is a simpler next step with a predictable side-effect profile.

Renal considerations also matter. Both drugs are cleared by proteolytic degradation rather than renal elimination, so neither requires dose adjustment in chronic kidney disease. Dulaglutide showed renal composite endpoint benefits in the REWIND renal sub-study (HR 0.85, 95% CI 0.77-0.93), adding another reason some nephrologists prefer to keep patients on it 10.

Monitoring After the Switch

Check A1C 12 weeks after initiating the new drug. This allows time for dose titration and steady-state pharmacokinetics. A fasting glucose or continuous glucose monitor (CGM) review at 4 weeks can catch early hypo- or hyperglycemia during the transition.

Weigh the patient at baseline and at each dose-escalation visit. Weight trajectory in the first 8 weeks predicts long-term response. Patients who lose <2% body weight by week 8 on tirzepatide 5 mg are less likely to achieve >10% total body weight loss even at maximum doses, based on SURMOUNT-1 responder analyses 8.

Monitor lipids at 6 months. Tirzepatide produced statistically significant reductions in triglycerides (19.6% vs 7.4% with semaglutide in SURPASS-2) and small improvements in HDL 1. Dulaglutide's lipid effects are more modest. A switch from dulaglutide to tirzepatide may improve the lipid panel independently of weight loss.

Patients on concurrent insulin should have their insulin dose reassessed at every visit during the first 12 weeks post-switch. The risk of hypoglycemia is highest during this window, particularly when switching from Trulicity to the more potent Mounjaro.